Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization (GlobeNewswire) - Mar 23, 2021 - "Plus Therapeutics, Inc...announced that it has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and supply of Plus' Rhenium NanoLiposome (RNL™) intermediate drug product.... Plus anticipates that the MSA will lead to clinical and commercial supply agreements for the drug product at the appropriate stage of development."
Licensing / partnership • Oncology
|